Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).

Hofman MS, Emmett L, Violet J, Y Zhang A, Lawrence NJ, Stockler M, Francis RJ, Iravani A, Williams S, Azad A, Martin A, McJannett M; ANZUP TheraP team, Davis ID.

BJU Int. 2019 Oct 22. doi: 10.1111/bju.14876. [Epub ahead of print]

PMID:
31638341
2.

Effect Sizes Hypothesized and Observed in Contemporary Phase III Trials of Targeted and Immunological Therapies for Advanced Cancer.

Lawrence NJ, Roncolato F, Martin A, Simes RJ, Stockler MR.

JNCI Cancer Spectr. 2018 Nov 27;2(4):pky037. doi: 10.1093/jncics/pky037. eCollection 2018 Oct.

3.

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.

N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2.

PMID:
31157964
4.

What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial.

Lawrence NJ, Martin A, Davis ID, Troon S, Sengupta S, Hovey E, Coskinas X, Kaplan R, Smith B, Ritchie A, Meade A, Eisen T, Blinman P, Stockler MR.

Kidney Cancer. 2018 Aug 1;2(2):123-131. doi: 10.3233/KCA-180038.

5.

Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer.

Nerlakanti N, Yao J, Nguyen DT, Patel AK, Eroshkin AM, Lawrence HR, Ayaz M, Kuenzi BM, Agarwal N, Chen Y, Gunawan S, Karim RM, Berndt N, Puskas J, Magliocco AM, Coppola D, Dhillon J, Zhang J, Shymalagovindarajan S, Rix U, Kim Y, Perera R, Lawrence NJ, Schonbrunn E, Mahajan K.

Mol Cancer Ther. 2018 Dec;17(12):2796-2810. doi: 10.1158/1535-7163.MCT-18-0602. Epub 2018 Sep 21.

PMID:
30242092
6.

Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours.

Lawrence NJ, Chan H, Toner G, Stockler MR, Martin A, Yip S, Wong N, Yeung A, Mazhar D, Pashankar F, Frazier L, McDermott R, Walker R, Tan H, Davis ID, Grimison P; ANZUP.

BMC Cancer. 2018 Aug 29;18(1):854. doi: 10.1186/s12885-018-4745-3.

7.

Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099.

Sun X, Ren Y, Gunawan S, Teng P, Chen Z, Lawrence HR, Cai J, Lawrence NJ, Wu J.

Leukemia. 2018 May;32(5):1246-1249. doi: 10.1038/s41375-018-0020-5. Epub 2018 Jan 30. No abstract available.

8.

Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.

Akuffo AA, Alontaga AY, Metcalf R, Beatty MS, Becker A, McDaniel JM, Hesterberg RS, Goodheart WE, Gunawan S, Ayaz M, Yang Y, Karim MR, Orobello ME, Daniel K, Guida W, Yoder JA, Rajadhyaksha AM, Schönbrunn E, Lawrence HR, Lawrence NJ, Epling-Burnette PK.

J Biol Chem. 2018 Apr 20;293(16):6187-6200. doi: 10.1074/jbc.M117.816868. Epub 2018 Feb 15.

9.

Blockade of ACK1/TNK2 To Squelch the Survival of Prostate Cancer Stem-like Cells.

Mahajan NP, Coppola D, Kim J, Lawrence HR, Lawrence NJ, Mahajan K.

Sci Rep. 2018 Jan 31;8(1):1954. doi: 10.1038/s41598-018-20172-z.

10.

ACK1/TNK2 Regulates Histone H4 Tyr88-phosphorylation and AR Gene Expression in Castration-Resistant Prostate Cancer.

Mahajan K, Malla P, Lawrence HR, Chen Z, Kumar-Sinha C, Malik R, Shukla S, Kim J, Coppola D, Lawrence NJ, Mahajan NP.

Cancer Cell. 2017 Jun 12;31(6):790-803.e8. doi: 10.1016/j.ccell.2017.05.003.

11.

Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics.

Ember SW, Lambert QT, Berndt N, Gunawan S, Ayaz M, Tauro M, Zhu JY, Cranfill PJ, Greninger P, Lynch CC, Benes CH, Lawrence HR, Reuther GW, Lawrence NJ, Schönbrunn E.

Mol Cancer Ther. 2017 Jun;16(6):1054-1067. doi: 10.1158/1535-7163.MCT-16-0568-T. Epub 2017 Mar 23.

12.

Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function.

Betts BC, Veerapathran A, Pidala J, Yang H, Horna P, Walton K, Cubitt CL, Gunawan S, Lawrence HR, Lawrence NJ, Sebti SM, Anasetti C.

Sci Transl Med. 2017 Jan 11;9(372). pii: eaai8269. doi: 10.1126/scitranslmed.aai8269.

13.

Valuing the benefits of new anticancer drugs.

Lawrence NJ, Salkeld G, Stockler MR, Karikios D.

Med J Aust. 2016 Jun 20;204(11):403-5. No abstract available.

PMID:
27318395
14.

Rapid Analysis of Copper Ore in Pre-Smelter Head Flow Slurry by Portable X-ray Fluorescence.

Burnett BJ, Lawrence NJ, Abourahma JN, Walker EB.

Appl Spectrosc. 2016 May;70(5):826-8. doi: 10.1177/0003702816638282. Epub 2016 Mar 22.

PMID:
27006021
15.

Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma.

Schneeberger VE, Ren Y, Luetteke N, Huang Q, Chen L, Lawrence HR, Lawrence NJ, Haura EB, Koomen JM, Coppola D, Wu J.

Oncotarget. 2015 Mar 20;6(8):6191-202.

16.

Development of novel ACK1/TNK2 inhibitors using a fragment-based approach.

Lawrence HR, Mahajan K, Luo Y, Zhang D, Tindall N, Huseyin M, Gevariya H, Kazi S, Ozcan S, Mahajan NP, Lawrence NJ.

J Med Chem. 2015 Mar 26;58(6):2746-63. doi: 10.1021/jm501929n. Epub 2015 Mar 17.

17.

ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1.

Mahajan K, Lawrence HR, Lawrence NJ, Mahajan NP.

J Biol Chem. 2014 Oct 10;289(41):28179-91. doi: 10.1074/jbc.M114.584425. Epub 2014 Aug 22.

18.

Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation.

Yang H, Lawrence HR, Kazi A, Gevariya H, Patel R, Luo Y, Rix U, Schonbrunn E, Lawrence NJ, Sebti SM.

Oncotarget. 2014 May 30;5(10):2947-61.

19.

Lysophosphatidic acid acyltransferase beta regulates mTOR signaling.

Blaskovich MA, Yendluri V, Lawrence HR, Lawrence NJ, Sebti SM, Springett GM.

PLoS One. 2013 Oct 31;8(10):e78632. doi: 10.1371/journal.pone.0078632. eCollection 2013.

20.

Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity.

Treviño JG, Verma M, Singh S, Pillai S, Zhang D, Pernazza D, Sebti SM, Lawrence NJ, Centeno BA, Chellappan SP.

Mol Cancer Ther. 2013 Dec;12(12):2722-34. doi: 10.1158/1535-7163.MCT-12-0719. Epub 2013 Oct 9.

21.

Development of new N-Arylbenzamides as STAT3 Dimerization Inhibitors.

Urlam MK, Pireddu R, Ge Y, Zhang X, Sun Y, Lawrence HR, Guida WC, Sebti SM, Lawrence NJ.

Medchemcomm. 2013 Jun;4(6):932-941.

22.

Resonant photoemission observations and DFT study of s-d hybridization in catalytically active gold clusters on ceria nanorods.

Zhou Y, Lawrence NJ, Wang L, Kong L, Wu TS, Liu J, Gao Y, Brewer JR, Lawrence VK, Sabirianov RF, Soo YL, Zeng XC, Dowben PA, Mei WN, Cheung CL.

Angew Chem Int Ed Engl. 2013 Jul 1;52(27):6936-9. doi: 10.1002/anie.201301383. Epub 2013 May 28. No abstract available.

PMID:
23716469
23.

A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation.

Zhang X, Sun Y, Pireddu R, Yang H, Urlam MK, Lawrence HR, Guida WC, Lawrence NJ, Sebti SM.

Cancer Res. 2013 Mar 15;73(6):1922-33. doi: 10.1158/0008-5472.CAN-12-3175. Epub 2013 Jan 15.

24.

Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2).

Pireddu R, Forinash KD, Sun NN, Martin MP, Sung SS, Alexander B, Zhu JY, Guida WC, Schönbrunn E, Sebti SM, Lawrence NJ.

Medchemcomm. 2012 Jun 1;3(6):699-709. Epub 2012 Jan 27.

25.

Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo.

Ucar DA, Magis AT, He DH, Lawrence NJ, Sebti SM, Kurenova E, Zajac-Kaye M, Zhang J, Hochwald SN.

Anticancer Agents Med Chem. 2013 May;13(4):595-602.

26.

Regulation of interlocking gene regulatory network subcircuits by a small molecule inhibitor of retinoblastoma protein (RB) phosphorylation: cancer cell expression of HLA-DR.

Pillai S, Szekeres K, Lawrence NJ, Chellappan SP, Blanck G.

Gene. 2013 Jan 10;512(2):403-7. doi: 10.1016/j.gene.2012.09.092. Epub 2012 Oct 3.

PMID:
23041127
27.

RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer.

Patel RA, Forinash KD, Pireddu R, Sun Y, Sun N, Martin MP, Schönbrunn E, Lawrence NJ, Sebti SM.

Cancer Res. 2012 Oct 1;72(19):5025-34. doi: 10.1158/0008-5472.CAN-12-0954. Epub 2012 Jul 30.

28.

Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors.

Lawrence HR, Martin MP, Luo Y, Pireddu R, Yang H, Gevariya H, Ozcan S, Zhu JY, Kendig R, Rodriguez M, Elias R, Cheng JQ, Sebti SM, Schonbrunn E, Lawrence NJ.

J Med Chem. 2012 Sep 13;55(17):7392-7416. doi: 10.1021/jm300334d. Epub 2012 Aug 30.

29.

HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1.

Caceres G, Robey RW, Sokol L, McGraw KL, Clark J, Lawrence NJ, Sebti SM, Wiese M, List AF.

Cancer Res. 2012 Aug 15;72(16):4204-13. doi: 10.1158/0008-5472.CAN-12-0743. Epub 2012 Jul 3.

30.

Ack1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancer.

Mahajan K, Coppola D, Rawal B, Chen YA, Lawrence HR, Engelman RW, Lawrence NJ, Mahajan NP.

J Biol Chem. 2012 Jun 22;287(26):22112-22. doi: 10.1074/jbc.M112.357384. Epub 2012 May 7.

31.

Controlling E. coli adhesion on high-k dielectric bioceramics films using poly(amino acid) multilayers.

Lawrence NJ, Wells-Kingsbury JM, Ihrig MM, Fangman TE, Namavar F, Cheung CL.

Langmuir. 2012 Mar 6;28(9):4301-8. doi: 10.1021/la2033725. Epub 2012 Feb 17.

PMID:
22339263
32.

Ack1 tyrosine kinase activation correlates with pancreatic cancer progression.

Mahajan K, Coppola D, Chen YA, Zhu W, Lawrence HR, Lawrence NJ, Mahajan NP.

Am J Pathol. 2012 Apr;180(4):1386-93. doi: 10.1016/j.ajpath.2011.12.028. Epub 2012 Feb 7.

33.

Enhanced anti-melanoma efficacy of interferon alfa-2b via inhibition of Shp2.

Win-Piazza H, Schneeberger VE, Chen L, Pernazza D, Lawrence HR, Sebti SM, Lawrence NJ, Wu J.

Cancer Lett. 2012 Jul 1;320(1):81-5. doi: 10.1016/j.canlet.2012.01.034. Epub 2012 Feb 1.

34.

Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors.

Li R, Martin MP, Liu Y, Wang B, Patel RA, Zhu JY, Sun N, Pireddu R, Lawrence NJ, Li J, Haura EB, Sung SS, Guida WC, Schonbrunn E, Sebti SM.

J Med Chem. 2012 Mar 8;55(5):2474-8. doi: 10.1021/jm201289r. Epub 2012 Feb 15.

35.

A novel mechanism by which small molecule inhibitors induce the DFG flip in Aurora A.

Martin MP, Zhu JY, Lawrence HR, Pireddu R, Luo Y, Alam R, Ozcan S, Sebti SM, Lawrence NJ, Schönbrunn E.

ACS Chem Biol. 2012 Apr 20;7(4):698-706. doi: 10.1021/cb200508b. Epub 2012 Jan 27.

36.

Nicotine-mediated induction of E-selectin in aortic endothelial cells requires Src kinase and E2F1 transcriptional activity.

Alamanda V, Singh S, Lawrence NJ, Chellappan SP.

Biochem Biophys Res Commun. 2012 Feb 3;418(1):56-61. doi: 10.1016/j.bbrc.2011.12.127. Epub 2012 Jan 3.

37.

Regulation of matrix metalloproteinase genes by E2F transcription factors: Rb-Raf-1 interaction as a novel target for metastatic disease.

Johnson JL, Pillai S, Pernazza D, Sebti SM, Lawrence NJ, Chellappan SP.

Cancer Res. 2012 Jan 15;72(2):516-26. doi: 10.1158/0008-5472.CAN-11-2647. Epub 2011 Nov 15. Erratum in: Cancer Res. 2012 Mar 1;72(5):1317.

38.

Defect engineering in cubic cerium oxide nanostructures for catalytic oxidation.

Lawrence NJ, Brewer JR, Wang L, Wu TS, Wells-Kingsbury J, Ihrig MM, Wang G, Soo YL, Mei WN, Cheung CL.

Nano Lett. 2011 Jul 13;11(7):2666-71. doi: 10.1021/nl200722z. Epub 2011 May 31.

PMID:
21627100
39.

Formation of a porous cerium oxide membrane by anodization.

Lawrence NJ, Jiang K, Cheung CL.

Chem Commun (Camb). 2011 Mar 7;47(9):2703-5. doi: 10.1039/c0cc04806b. Epub 2011 Jan 13.

PMID:
21234482
40.

Critical role of IRF-8 in negative regulation of TLR3 expression by Src homology 2 domain-containing protein tyrosine phosphatase-2 activity in human myeloid dendritic cells.

Fragale A, Stellacci E, Ilari R, Remoli AL, Lanciotti A, Perrotti E, Shytaj I, Orsatti R, Lawrence HR, Lawrence NJ, Wu J, Rehli M, Ozato K, Battistini A.

J Immunol. 2011 Feb 15;186(4):1951-62. doi: 10.4049/jimmunol.1000918. Epub 2011 Jan 10.

41.

Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs.

Scott LM, Chen L, Daniel KG, Brooks WH, Guida WC, Lawrence HR, Sebti SM, Lawrence NJ, Wu J.

Bioorg Med Chem Lett. 2011 Jan 15;21(2):730-3. doi: 10.1016/j.bmcl.2010.11.117. Epub 2010 Dec 4.

42.

Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity.

Mahajan K, Challa S, Coppola D, Lawrence H, Luo Y, Gevariya H, Zhu W, Chen YA, Lawrence NJ, Mahajan NP.

Prostate. 2010 Sep 1;70(12):1274-85. doi: 10.1002/pros.21163.

43.

Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112.

Chen L, Pernazza D, Scott LM, Lawrence HR, Ren Y, Luo Y, Wu X, Sung SS, Guida WC, Sebti SM, Lawrence NJ, Wu J.

Biochem Pharmacol. 2010 Sep 15;80(6):801-10. doi: 10.1016/j.bcp.2010.05.019. Epub 2010 May 25.

44.

The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane.

Berndt N, Yang H, Trinczek B, Betzi S, Zhang Z, Wu B, Lawrence NJ, Pellecchia M, Schönbrunn E, Cheng JQ, Sebti SM.

Cell Death Differ. 2010 Nov;17(11):1795-804. doi: 10.1038/cdd.2010.63. Epub 2010 May 21.

45.

Targeting protein tyrosine phosphatases for anticancer drug discovery.

Scott LM, Lawrence HR, Sebti SM, Lawrence NJ, Wu J.

Curr Pharm Des. 2010 Jun;16(16):1843-62. Review.

46.

Combretastatin-like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-aryl chalcones.

Ducki S, Mackenzie G, Greedy B, Armitage S, Chabert JF, Bennett E, Nettles J, Snyder JP, Lawrence NJ.

Bioorg Med Chem. 2009 Nov 15;17(22):7711-22. doi: 10.1016/j.bmc.2009.09.044. Epub 2009 Oct 2.

PMID:
19837594
47.

Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity.

Ducki S, Rennison D, Woo M, Kendall A, Chabert JF, McGown AT, Lawrence NJ.

Bioorg Med Chem. 2009 Nov 15;17(22):7698-710. doi: 10.1016/j.bmc.2009.09.039. Epub 2009 Sep 25.

PMID:
19837593
48.

Cell shape changes indicate a role for extrinsic tensile forces in Drosophila germ-band extension.

Butler LC, Blanchard GB, Kabla AJ, Lawrence NJ, Welchman DP, Mahadevan L, Adams RJ, Sanson B.

Nat Cell Biol. 2009 Jul;11(7):859-64. doi: 10.1038/ncb1894. Epub 2009 Jun 7.

PMID:
19503074
49.

Identification of a disruptor of the MDM2-p53 protein-protein interaction facilitated by high-throughput in silico docking.

Lawrence HR, Li Z, Yip ML, Sung SS, Lawrence NJ, McLaughlin ML, McManus GJ, Zaworotko MJ, Sebti SM, Chen J, Guida WC.

Bioorg Med Chem Lett. 2009 Jul 15;19(14):3756-9. doi: 10.1016/j.bmcl.2009.04.124. Epub 2009 May 3.

50.

Topical thymidine dinucleotide application protects against UVB-induced skin cancer in mice with DNA repair gene (Ercc1)-deficient skin.

Lawrence NJ, Song L, Doig J, Ritchie AM, Brownstein DG, Melton DW.

DNA Repair (Amst). 2009 May 1;8(5):664-71. doi: 10.1016/j.dnarep.2009.01.020. Epub 2009 Mar 4.

PMID:
19264557

Supplemental Content

Loading ...
Support Center